Learn More
BACKGROUND We report the first randomized, Phase II trial of ramucirumab, an anti-vascular endothelial growth factor receptor-2 monoclonal antibody, as front-line therapy in patients with advanced(More)
Tigatuzumab is the humanized version of the agonistic murine monoclonal antibody TRA-8 that binds to the death receptor 5 and induces apoptosis of human cancer cell lines via the caspase cascade. The(More)
8016 Background: The combination of rituximab plus CHOP chemotherapy (R-CHOP) is widely used as standard of care for DLBCL; however, long-term survival is low in patients (pts) with high (IPI) risk(More)
PURPOSE To evaluate the activity of panobinostat in refractory renal carcinoma. PATIENTS AND METHODS Patients with advanced clear cell renal carcinoma who had received previous therapy with at(More)